PolyU's Groundbreaking Discovery: Antibody Targeting Liver Cancer Protein
Liver cancer is a devastating disease, claiming the lives of countless individuals worldwide. But a recent study from The Hong Kong Polytechnic University (PolyU) offers a glimmer of hope, presenting a novel antibody that could revolutionize the treatment of this deadly disease.
Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, is a growing concern, affecting approximately a quarter of the global population. This condition is a significant risk factor for liver cancer, as it leads to excessive fat accumulation in the liver, impairing its function and potentially progressing to cancer. Current treatment options for MASLD-induced liver cancer are limited, and the effectiveness of immunotherapies is suboptimal.
A groundbreaking study led by Prof. Terence LEE, Associate Head and Professor of the PolyU Department of Applied Biology and Chemical Technology, has revealed a crucial protein secreted by fat cells that accelerates tumor growth. Through mass spectrometry, the team confirmed that patients with MASLD-induced liver cancer had elevated levels of this protein, known as fatty acid-binding protein 4 (FABP4).
Further investigations showed that FABP4 activates pro-proliferative signaling pathways within cells, causing cancer cells to multiply and grow more rapidly. Prof. Lee's team has successfully developed a monoclonal antibody that neutralizes FABP4, inhibiting the growth and proliferation of cancer stem cells and enhancing the ability of immune cells to combat cancer.
Prof. Lee stated, "This neutralizing antibody against FABP4 demonstrates significant potential in inhibiting tumor growth and activating immune cells, providing a complementary approach to current immunotherapy strategies. Our findings highlight that targeting adipocyte-derived FABP4 holds promise for treating MASLD-induced liver cancer."
The research, supported by the Innovation and Technology Fund, has been published in the Journal of Clinical Investigation. PolyU has filed a non-provisional patent for the developed antibody and is continuing to optimize its binding affinity for future clinical applications.
But here's where it gets controversial... While the study presents a promising breakthrough, it raises questions about the potential side effects of targeting FABP4. Some experts argue that FABP4 plays a crucial role in energy metabolism, and inhibiting it could have unintended consequences. This opens up a discussion on the need for further research to fully understand the implications of this treatment approach.
What are your thoughts on this groundbreaking discovery? Do you think it could be a game-changer in the fight against liver cancer? Share your opinions and engage in the conversation in the comments section below.
